<DOC>
	<DOC>NCT00197951</DOC>
	<brief_summary>Alcohol dependent patients show comorbid psychiatric symptoms, related to malfunction of dopamine, norepinephrine and serotonin neurotransmission, during early recovery. Ziprasidone can improve malfunctioning of these disregulated systems, thereby improving anxiety, depression, anhedonia, anger, and alcohol craving.</brief_summary>
	<brief_title>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism</brief_title>
	<detailed_description>60 alcohol-dependent patients will be included, once finished alcohol detoxification treatment.Thirty patients will receive ziprasidone treatment, in progressively increasing doses, starting from 40 mg per day, and the other 30 patients will receive placebo, in a double blind procedure</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>DSMIVTR criteria for alcohol dependence disorder Age between 18 65 years old. Score 7 or higher in the GHQ28 scale. More than 30 days without drinking alcohol. Severe medical disorders. Psychotic or bipolar disorders severely decompensated requiring antipsychotic medication. Opiate, cocaine or benzodiazepine dependence disorders, requiring more than one week of detoxification treatment. Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Psychiatric symptoms associated to alcoholism recovery</keyword>
	<keyword>Alcoholism treatment</keyword>
	<keyword>Alcohol craving</keyword>
	<keyword>Relapse to heavy drinking</keyword>
	<keyword>Abuse of other substances during alcoholism recovery</keyword>
</DOC>